Hospira MitoXANTRONE Injection, USP (concentrate) 25 mg/12.5 mL vial

Ülke: Avustralya

Dil: İngilizce

Kaynak: Department of Health (Therapeutic Goods Administration)

Aktif bileşen:

mitoxantrone (mitozantrone) hydrochloride, Quantity: 2.33 mg/mL (Equivalent: mitoxantrone, Qty 2 mg/mL)

Mevcut itibaren:

Hospira Australia Pty Ltd

INN (International Adı):

mitoxantrone (mitozantrone) hydrochloride

Farmasötik formu:

Injection

Kompozisyon:

Excipient Ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride; sodium metabisulfite

Uygulama yolu:

Intravenous Infusion

Paketteki üniteler:

1 x 12.5 mL vial

Sınıf:

Medicine Listed (Export Only)

Reçete türü:

Not scheduled. Not considered by committee

Terapötik endikasyonlar:

Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drus(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.

Ürün özeti:

Visual Identification: A clear, dark blue solution; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store between 15-25 degrees Celsius

Yetkilendirme durumu:

Licence status A

Yetkilendirme tarihi:

2007-08-20